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CASE PRESENTATION
The patient presented herein, is a 29-year-
old man with history of unilateral alkaline 
chemical injury 14 years ago. Upon referral, 
visual acuity was 20/20 and the examination 
was unremarkable in the right eye. Vision 
was hand motions (HM) in his left eye and a 
small angle exotropia (10-15 Prism Diopters) 
was evident. Slitlamp examination revealed 
severe corneal opacification and vascularization 
(Fig. 1). Intraocular pressure (IOP) was 13 and 
10 mmHg in the right and left eyes, respectively. 
B-scan ultrasonography ruled out gross posterior 
segment pathologies and impression cytology 
revealed total limbal stem cell deficiency (LSCD) 
in the left eye. 
The injured eye underwent cultivated 
autologous stem cell transplantation on amniotic 
membrane (AM) after punctal cauterization. The 
patient received a topical steroid (betamethasone 
0.1%, Sina-Daru, Tehran, Iran), and an antibiotic 
(chloramphenicol 0.5%, Sina-Daru, Tehran, Iran). 
Antibiotic drops were continued for 1 to 2 weeks 
until complete epithelialization. Steroid drops 
were tapered off according to the level of ocular 
inflammation over 6-8 weeks. A preservative-
free artificial tear (Artelac, Bausch and Lomb, 
USA) was used for lubrication as needed. The 
patient received systemic prednisolone 1 mg/
kg (Sina-Daru, Tehran, Iran) for 3 to 4 weeks. 
Visual acuity in the left eye improved to counting 
fingers at 75 cm along with modest decrease in 
corneal vascularization and opacity 3 months 
after the procedure (Fig. 2). 
Due to deep corneal stromal opacification, 
penetrating keratoplasty (PKP) was performed 6 
months later. One month after PKP, visual acuity 
improved to 20/120. The patient complained 
of diplopia which was due to improvement in 
vision and the small angle exotropia. Six weeks 
later, IOP increased to 32 mmHg which was 
controlled by topical timolol 0.5% (Sina-Daru, 
Tehran, Iran) two times per day and systemic 
acetazolamide 250mg, three times per day. 
Cup-disc ratio was 0.3. Systemic acetazolamide 
was discontinued due to elevated liver enzymes 
and replaced by topical dorzolamide 2% (Sina-
Figure 1.  Slitlamp  appearance  of  the  left  cornea 
demonstrating total vascularized opacity.
Figure 2. Three months after stem cell transplantation 
epithelial  transparency  has  increased,  while  corneal 
vascularization and opacification have decreased.Challenging Case; Limbal Stem Cell Deficiency
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Daru, Tehran, Iran) two times per day. 
Eight weeks after corneal transplantation, 
the patient developed epithelial rejection, 
which was treated with topical steroids. Four 
months after surgery, IOP rose to 30 mmHg 
and brimonidine 0.2% (Alphagan, Allergan Inc., 
Irvine, USA) and latanoprost 0.005% (Xalatan, 
Pfizer Inc., New York, USA) were added to 
the regimen. Five months after PKP, visual 
acuity improved to 20/80 but IOP was poorly 
controlled (Fig. 3). The patient underwent 
Ahmed Glaucoma Valve (AGV) surgery. Two 
months later, a mild posterior subcapsular 
cataract was observed. Five month after AGV, 
corneal endothelial and subepithelial rejection 
were observed which was aggressively treated 
with systemic prednisolone and topical 
betamethasone. Overall, the patient experienced 
three attacks of corneal endothelial rejection 
5, 9 and 16 months after AGV. There was a 
slightly progressive vascularization in the graft 
periphery 8 months after PKP. 
Considering multiple episodes of corneal 
endothelial rejection and progressive corneal 
conjunctivalization in an eye with defective 
ocular  surface,  systemic  cyclosporine 
(Sandimmune®, Novartis Pharma Stein AG, 
Stein, Switzerland) 300 mg per day was 
started. One month later, it was replaced by 
mycophenolate mofetil (Cellcept®, Hoffmann-
La Roche Inc., Nutley, USA) 2 grams per day 
due to elevated liver enzymes. Two weeks 
later liver enzymes levels improved but 2 
months thereafter, rose critically again and 
mycophenolate was also discontinued. After 
that, the patient was put on fluorometholone 
0.25% eye drops once daily together with topical 
cyclosporine 2%. 
One year after PKP, impression cytology 
confirmed corneal conjunctivalization in the 
superior and inferior temporal quadrants by 
the presence of goblet cells on the corneal side 
of the specimens. About 20 months after PKP, 
vascularization and conjunctivalization was 
continuing but did not reach the central 5 mm 
zone of the cornea (Fig. 4). At final visit, visual 
acuity was maintained at 20/80 and IOP was 
16 mmHg without any glaucoma medications.
Herein we present the views of two anterior 
segment specialists on the management of 
LSCD in this patient.
Ahmad Kheirkhah, MD
To maximize the outcomes of transplantation of 
ex vivo cultured limbal epithelial cells (LECs), 
several issues need to be considered. First of 
all, the ocular surface should be optimized 
before performing any kind of limbal stem 
cell transplantation. Although both puncti 
of the recipient eye were cauterized prior to 
transplantation, it is unclear whether the ocular 
surface was actually ready for surgery. For 
example, it has not been mentioned whether 
the recipient eye had any other factor which 
may interfere with ocular surface health, 
Figure 3.  Slitlamp  appearance  5  months  after  corneal 
transplantation.
Figure 4.  The  left  cornea  at  last  visit  demonstrates 
peripheral conjunctivalization and a clear center.Challenging Case; Limbal Stem Cell Deficiency
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such as surface inflammation, symblepharon, 
closure and blinking problems, or lid margin 
abnormalities.
After any form of ex vivo culture of LECs 
and before transplantation of the product to the 
ocular surface, it is necessary to demonstrate 
that the product really contains viable stem 
cells. A number of methods have been employed 
for this purpose such as functional assay of 
colony forming ability of transplanted cells, 
immunohistological assays, evidence of donor 
cell survival, and confocal scanning. In this 
case report, the evaluation method for the 
product has not been stated. Transplantation 
of a product with inadequate viable stem cells 
can result in long-term failure, which finally 
developed in this patient.
Although the surgical technique for 
transplantation of ex vivo cultured LECs is 
fairly similar in different studies, postoperative 
medical regimens may differ among them. 
The basic principles of this regimen include 
immediate control of inflammation, prophylaxis 
against infection, and mechanical protection of 
the graft. Application of autologous serum eye 
drops may further optimize the environment 
for stem cell survival. The early postoperative 
course of the patient has not been mentioned 
which may be a clue to final graft survival.
The  patient  in  this  report  showed 
improvement in visual acuity with moderate 
decrease in corneal vascularization and 
opacification 3 months after surgery (Fig. 2). 
However, these could not be considered to 
be absolute measures of success. There were 
still many areas of corneal vascularization 
with  a  clinical  appearance  of  residual 
conjunctivalization (Fig. 2). There is no data 
on fluorescein staining patterns or the results 
of impression cytology at this postoperative 
time point. Due to lack of these data, there is 
a possibility that the patient was still suffering 
from residual LSCD at that time. It should be 
mentioned that in addition to clinical findings, 
a more definitive way to evaluate the success of 
surgery is to perform impression cytology on 
the corneal surface postoperatively. This test, 
which was not performed in the case report, 
is necessary before proceeding with corneal 
transplantation. This may explain why the 
patient finally developed partial LSCD.
Performing an eccentric full-thickness graft 
in a vascularized cornea (Fig. 3) should be 
considered as a high risk corneal graft. This is 
why the patient developed multiple episodes 
of graft rejection. In these cases, if there is no 
full-thickness corneal involvement, it is always 
preferable to perform lamellar rather than full-
thickness corneal transplantation.
The postoperative management of this 
immunologically high risk graft is vital in 
determining the outcome. The main measure 
to be used for prevention of rejection in high 
risk grafts is immunosuppression. Although 
corticosteroids have traditionally been used for 
this purpose, new agents have been available 
in the past years. In high risk patients, topical 
steroids are used frequently in the postoperative 
period, followed by their long-term use if 
there is no contraindication. Sometimes, low 
dose steroids need to be used indefinitely after 
surgery. Therefore, potential complications of 
steroids, such as cataracts, glaucoma, delayed 
wound healing, and infectious keratitis should 
seriously be considered. Systemic steroids can 
also be used as an adjunct to topical therapy, 
particularly in high risk cases with concomitant 
systemic inflammatory diseases. Recently, 
steroids with lower rates of complications have 
been introduced; examples include loteprednol 
etabonate and fluorometholone which can be 
used for keratoplasty patients who require 
long-term maintenance therapy. 
In addition to corticosteroids, cyclosporine 
A (CsA), a calcineurin inhibitor, has been used 
extensively in organ transplantations including 
high risk corneal allografts. Many studies have 
demonstrated the effectiveness of CsA, either 
topically or systemically, to reduce rejection 
rates in high risk keratoplasty patients. Although 
0.05% CsA is commercially available, a 2% 
concentration has been shown to be effective 
for this purpose. Oral CsA may be used in 
very high-risk cases when topical medications 
may not be sufficient to prevent corneal graft 
rejection. However, oral CsA is associated with 
a number of dose-related side effects, most 
commonly nephrotoxicity, hypertension, and Challenging Case; Limbal Stem Cell Deficiency
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hepatotoxicity, which developed in this case. 
Various other systemic immunosuppressive 
agents have been used in patients with high risk 
corneal grafts such as tacrolimus, azathioprine, 
mycophenolate mofetil, and rapamycin, 
sometimes in combination. However, all of 
these agents may be associated with adverse 
effects, which developed in this case after using 
mycophenolate. In my personal experience, 
the preferable initial immunosuppressive 
medication is topical 2% CsA which may be 
used alone or in combination with topical 
steroids. This may be why the patient did not 
develop any episode of graft rejection while 
on topical CsA.
This case report shows how difficult it 
may be to manage patients with significant 
ocular surface disease. A comprehensive 
multidisciplinary approach is necessary to deal 
with these grave eye conditions. 
Farid Karimian, MD
This 29-year-old man with severe vascularization, 
conjunctivalization and diffuse haziness of the 
cornea has unilateral total LSCD. He had history 
of chemical injury 14 years before presentation. 
At this stage, any type of corneal transplantation 
(penetrating or lamellar) would have a short 
survival and may fail rapidly. Because the right 
eye is normal in appearance and has no history 
of exposure to chemical agents, limbal stem 
cells could be harvested for ex vivo expansion. 
This technique which has become available in 
some centers in recent years, enables patients 
to make benefit of their own stem cells. This 
technique brings hope for traditionally poor 
chance cases with LSCD. At this stage it is very 
important to optimize the status of the fornices. 
Severe symblepharon and foreshortening of the 
fornices prevents adequate tear film lubrication 
and lid function. Therefore, reconstruction of 
the fornices and release of symblepharon using 
amniotic membrane can be helpful.
After limbal stem cell transplantation, 
it would be better to use preservative-free 
medications. The medications used in this case 
are not preservative-free and can be toxic to 
the transplanted tissue. 
After PKP in cases who are considered to be 
high risk due to previous limbal stem cell (LSC) 
transplantation, immunosuppressive treatment 
must be used. Steroids alone are not enough and 
can be used in the immediate post-PKP period, 
but systemic or topical immunosuppression 
with medications such as cyclosporine A 
(Sandimmune®) or mycophenolate mofetil 
(Cellcept®) are important preventive measures 
against rejection of corneal transplants. It would 
be better to start these medications earlier and 
prior to immune system activation. 
IOP rise with coticosteroids can be due to 
steroid responsiveness. This risk is higher with 
topical betamethasone than other steroids. If the 
use of these types of medications is mandatory, 
alternative medications, e.g. fluorometholone 
or loteprednol can be considered. 
In summary, the management of LSCD 
has remarkably changed over the recent 
years. Cultivation of LSC and application 
of immunosuppressive medications will 
help clinicians improve the final outcomes. 
Glaucoma is a sight-threatening complication 
in these cases. Manipulation of cicatrized and 
scarified conjunctiva, extensive use of steroids, 
and multiple operations are important factors 
predisposing to glaucoma. 
Editor’s Note
Surgical management of LSCD depends on the 
laterality and severity of corneal involvement. 
Partial LSCD can be managed using amniotic 
membrane transplantation (AMT) or sequential 
epitheliectomy. In partial or total unilateral 
cases, conjunctival-limbal autograft (CLAU) is a 
good choice. Recently, transplantation of limbal 
epithelial stem cells cultivated on carriers such 
as AM or transplantation of ex vivo cultured 
autologous oral mucosal epithelial cells has 
been considered as alternative procedures for 
unilateral or bilateral LSCD. 
The main objective of any kind of stem 
cell transplantation is to supply new corneal 
epithelium for a prolonged, if not indefinite, 
period of time so that patients can be relieved 
from annoying photophobia and regain useful 
vision. Cultivation of a small part of the limbus Challenging Case; Limbal Stem Cell Deficiency
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may provide epithelial progenitor cells, which 
might survive for a while on the ocular surface. 
In eyes with superficial corneal vascularization 
and pannus, a single procedure is frequently 
enough. However, if there is concomitant 
deep corneal stromal scarring, penetrating 
or lamellar keratoplasty is needed to restore 
vision. Drawback to CLAU and conjunctival-
limbal allograft (CLAL) is that due to removal 
of fairly large segments of limbal tissue, the 
donor eye is at risk of surgically induced LSCD. 
The use of autologous cultivated limbal stem 
cell transplantation has been suggested to 
overcome this limitation. Cultivating a small 
amount of limbal tissue provides adequate 
limbal stem cells for treatment of total LSCD.
Use of AM as a carrier medium for 
cultivated limbal stem cells entails the following 
advantages. Its stromal matrix is similar to 
conjunctival basement membrane and is a 
suitable medium for growth of limbal stem 
cells, it is antigen-free and resorbed gradually. 
AM facilitates ocular surface epithelialization, 
it down-regulates inflammatory cytokines, 
facilitates epithelial cell differentiation and 
may be used for ocular surface reconstruction.
The use of ex vivo cultured limbal epithelial 
stem cells for treatment of corneal LSCD in 
humans was first described by Pellegrini et al 
in 1997. Since then several additional reports 
on the use of this technology to treat patients 
have been published. In addition, other studies 
have reported the transplantation of ex vivo 
cultured autologous oral mucosal epithelial 
cells to treat LSCD. Numerous reviews have 
dealt with the scientific theory and evidence 
behind this treatment. In almost all studies, 
the authors conclude that this method is a 
successful procedure to treat unilateral corneal 
stem cell deficiency. Some key questions still 
need to be answered. The exact proportion of 
stem cells present in ex vivo cultured limbal 
epithelial cell sheets is unclear and needs to be 
determined. The behavior of limbal epithelial 
stem cells post-transplantation also needs to be 
elucidated. It has been proposed that the success 
of this treatment relies on the re-integration of 
exogenous cultured limbal stem cells into the 
ocular surface, and that these cells function to 
continuously replenish the corneal epithelium. 
It is interesting that despite the different 
methodologies employed, the success rate and 
outcomes are remarkably similar. 
The surgeon subsequently performed 
optical PKP in this case. He selected fresh donor 
cornea with a very good coverage of epithelial 
cells; therefore some transient amplifying cells 
(TACs), which support corneal clarity have been 
theoretically transferred by the corneal graft. 
It is not possible to judge whether the cause of 
corneal clarity is related to TACs transferred 
by the corneal graft or due to transplanted 
epithelial progenitor cells cultivated on the AM. 
However, it seems that the period of corneal 
clarity was relatively longer than usual corneal 
grafts without stem cell transplantation. 
In  summary,  cultivated  stem  cell 
transplantation on AM might be an effective 
way to improve the health of the injured ocular 
surface. Despite uncertainties, published clinical 
evidence supports the continued advancement of 
this procedure for treatment of corneal epithelial 
stem cell deficiency. To date, this procedure 
has been regarded as experimental, but in the 
light of the clinical outcomes, it seems that it 
has the potential to become a viable option for 
treatment of many patients with severe limbal 
stem cell deficiency.
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